Short-term safety assessment in the use of intravenous zoledronic acid in children.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15520785.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The clinical side effects of the potent new bisphosphonate zoledronic acid in children are unknown. In this study of 34 children with various bone disorders, the frequency of postinfusion flu-like illness, hypocalcemia, and hypophosphatemia was 85%, 74%, and 82%, respectively. No renal side effects were detected after up to 3 consecutive infusions.
Medical subject headings
- Bone Resorption
- Diphosphonates
- Imidazoles